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Hydroamination reactions involving the addition of
an amine to an inactivated alkene are entropically
prohibited and require strong chemical catalysts.
While this synthetic process is efficient at generating
substituted amines, there is no equivalent in small
molecule-mediated enzyme inhibition. We report an
unusual mechanism of proteasome inhibition that
involves a hydroamination reaction of alkene deriva-
tives of the epoxyketone natural product carmaphy-
cin. We show that the carmaphycin enone first forms
a hemiketal intermediate with the catalytic Thr1 resi-
due of the proteasome before cyclization by an
unanticipated intramolecular alkene hydroamination
reaction, resulting in a stable six-memberedmorpho-
line ring. The carmaphycin enone electrophile, which
does not undergo a 1,4-Michael addition as previ-
ously observed with vinyl sulfone and a,b-unsatu-
rated amide-based inhibitors, is partially reversible
and gives insight into the design of proteasome in-
hibitors for cancer chemotherapy.
INTRODUCTION
Hydroamination of unactivated alkenes is a challenging process
because such reactions are generally not very exothermic and
are entropically disfavored (Beller et al., 2004; Hultzsch, 2005).
In general, these reactions require protonation of the alkene
p-bond, leading to a carbocation intermediate that is then
attacked by the amine nucleophile (Beller et al., 2004). Whereas
this process can be promoted by alkali, transition, or rare earth
metals, as well as by Lewis or Brønsted acids and bases (Beller
et al., 2004; Schlummer and Hartwig, 2002; Hultzsch, 2005), no
equivalent in small molecule-mediated enzyme inhibition has782 Chemistry & Biology 21, 782–791, June 19, 2014 ª2014 Elsevierbeen reported. The entropic penalty for a biochemical hydroami-
nation reaction, however, may conceivably be overcome by pre-
organization in an enzyme reactive site. In this work, we report
enzyme inhibition mediated by hydroamination using protea-
some inhibitors derived from natural products. The scaffolds of
these small molecules interact tightly with the protein, which
facilitates hydroamination by the enzyme N-terminal amine.
The proteasome functions as the central hub of nonlysosomal
cellular proteolysis where it mediates a number of key processes
such as cell cycle control, cell differentiation, immune response,
amino acid recycling, and apoptosis (Goldberg, 2007; Murata
et al., 2009). These biological processes can thus be manipu-
lated through the addition of small molecules that selectively
target the proteolytically active b subunits of the proteasome
(Kisselev et al., 2012; Moore et al., 2008; Borissenko and Groll,
2007). Due to the importance of the proteasome to malignant
cells and the immune process, it is considered a biological target
of high interest for pharmaceutical development. Two protea-
some inhibitors, the epoxyketone carfilzomib (Kyprolis) and the
peptide boronate bortezomib (Velcade), are now used clinically
as anticancer agents and others are in development.
Several proteasome inhibitors have been reported from natu-
ral and synthetic sources and include both noncovalent and
covalent inhibitors (Kisselev et al., 2012). The covalent protea-
some inhibitors can display reversible or irreversible inhibition
profiles and present, in most cases, a peptidic core and an elec-
trophilic warhead. The peptidic core is responsible for forming a
stable antiparallel b sheet with the enzyme, which in turn posi-
tions the warhead in ideal geometry for covalent attachment of
the Thr1 proteasome catalytic residue. The Thr1 side chain oxy-
gen (Thr1Og) is the nucleophile responsible for the attack on
electrophilic substrates, including the natural peptidic substrate
and several classes of inhibitor electrophiles, thus forming cova-
lent adducts (Kisselev et al., 2012). Taking advantage of the
inhibitor stability and warhead positioning conferred by the
peptidic core of proteasome inhibitors, we used the recently
discovered natural product carmaphycin (1; Pereira et al.,Ltd All rights reserved
Figure 1. Natural Product Proteasome Inhibitors
Carmaphycin A (1), syringolin A (2), and derivatives 3–6.
Table 1. Inhibitory Activity of Carmaphycin and Analogs as
Measured in Human Cell Assays and with the Purified Yeast 20S
Proteasome
ChTL (b5)a TL (b2)b H-460c HCT-116d
1 1.5 ± 0.2 46.2 ± 6.0 16.4 ± 2.7 19.4 ± 0.1
3 1.2 ± 0.1 112.4 ± 7.0 19.6 ± 2.4 10.7 ± 2.3
4 164.5 ± 5.6 >50,000 1,667.0 ± 82.0 727.4 ± 167.1
IC50 values (nM) are presented.
aPurified yeast proteasome, Suc-LLVY-Amc is a peptide substrate to
specifically determine ChTL activity.
bPurified yeast proteasome, Ac-LRR-Amc is a peptide substrate to
specifically determine TL activity.
cH-460 human lung cancer cell line.
dHCT-116 human colon cancer cell line.
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phile in interacting with enone electrophiles.
Structurally, 1 features a leucine-derived a0,b0-epoxyketone
warhead (the P1 residue) directly connected to amethionine sulf-
oxide (the P2 residue), which in turn is connected to a valine (the
P3 residue) and an alkyl chain terminal tail (Figure 1). a0,b0-epoxy-
ketones, as exemplified in 1, the bacterial natural product epox-
omicin (Groll et al., 2000; Meng et al., 1999), and its recently US
Food and Drug Administration (FDA)-approved derivative carfil-
zomib (Molineaux, 2012) are potent, selective, and irreversible
proteasome inhibitors. Epoxyketone warheads form stable mor-
pholine derivatives with the active site Thr1 residues in the six
proteolytic sites of the 20S proteasome core particle (Groll
et al., 2000; Meng et al., 1999). The warhead carbonyl and
epoxide undergo two successive nucleophilic attacks performed
by Thr1Og and Thr1N, respectively (Groll et al., 2000).
Another class of proteasome inhibitor warheads of interest are
a,b-unsaturated systems, such as a,b-unsaturated amides, as
seen in the proteasome inhibitor and plant pathogen virulence
factor syringolin A (Groll et al., 2008; 2), and vinylsulfones (Kisse-
lev et al., 2012). These undergo 1,4-Michael addition with the
Thr1Og nucleophile, forming a one-step irreversible covalent
adduct with Thr1Og.
We thushypothesized that replacing the epoxyketonewarhead
in 1 with a complementary a,b-unsaturated carbonyl as in 2
would probe the plasticity of the proteasome and change the
nature of the chemical reactions between the inhibitor and the
enzyme. Herein we report an unusual mechanism of proteasome
inhibition that involves a hydroamination reaction of alkene
derivatives of the carmaphycin class of proteasome inhibitors.
RESULTS
Synthesis of Carmaphycin Derivatives
Due to the unstable redox properties of the methionine sulfoxide
at the P2 residue position of natural carmaphycin A (1), we re-Chemistry & Biology 21,placed this residue with N,N-dimethylglutamine. Based on alter-
ations to our original total synthesis (Pereira et al., 2012) of 1, we
prepared epoxyketone 3, enones 4 and 5, and ketone 6. These
synthetic analogs along with natural product 1 were used in
this study to explore and compare the relative inhibitory effect
of different ketone derivatives in the carmaphycin series. The
complete synthetic procedures are reported in the Supplemental
Experimental Procedures and Experimental Procedures.
Activity Assays
We first interrogated the chymotrypsin-like (ChTL) inhibitory
activity of the carmaphycin analog 3 and measured a similar
potency in comparison with the natural compound 1 (1.2 nM
versus 1.5 nM with the purified proteasome, respectively), sug-
gesting the functional similarity of their P2 residues (Table 1).
We next analyzed the carmaphycin/syringolin chimera 4, which
also displayed high potency with nanomolar inhibition of the
purified proteasome, albeit with a 100-fold loss in activity
(164 nM). The proteasome trypsin-like activity (TL, b2 subunit)
was also measured, showing preferable inhibitor binding to
ChTL over TL for the three inhibitors tested. Overall, the relative
potencies of ChTL inhibition matched the cell toxicity properties
of these new derivatives, with compound 3 being of highest
potency, whereas 4 displayed decreased activity yet still had
effects in the nanomolar range (Table 1).
We further showed the importance of the alkene or epoxide
groups in the warhead of these inhibitors by preparing and
testing saturated ketone 6. Compound 6 was not active in the
enzyme nor in the cell-based assays, even at concentration
as high as 1 mM.
To more fully explore the consequence of replacing the epox-
yketone in 3 with the enone warhead in 4, we separately incu-
bated 1, 3 and 4 with the yeast and human 20S proteasomes
to measure their relative binding properties (Figures S1 and S2
available online). Compounds 1 and 3 showed a clear reversible
mode of binding after 2 hr of incubation with the ligand (Figures
S1A and S1D). However, the reversibility was less evident after
6 hr (Figures S1B and S1E) and after 24 hr was irreversible (Fig-
ures S1C and S1F). This inhibition profile suggests a two-step
mechanism of interaction with the proteasome, much like that
observed for the prototype epoxomicin (Groll et al., 2000;
Meng et al., 1999), and is highly anticipated for epoxyketone
warheads. Epoxyketones undergo a fast reversible inhibition782–791, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 783
Figure 2. Crystal Structures of the Yeast 20S Proteasome Binding the Natural Product Carmaphycin A (1) and Derivatives Containing
Epoxyketone and Enone Warheads
(A–H) General view of the ChTL catalytic unit binding 1 (A) and detailed view of 1 (B) and 3 (C) epoxyketone warheads. The enone chimera 4 is shown in (D) and a
detailed view of the enone warhead bound to the b2 (TL) and b5 (ChTL) subunits are presented in (E) and (F), respectively. Ligands are contoured by the 2Fo-Fc
omit maps at 1s (blue net). A hemiketal adduct was trapped at the TL subunit binding compound 4 (E), unequivocally showing a 1,2 addition reaction of the
Thr1Og to the enone carbonyl. In contrast, a cyclic adduct was found at the ChTL subunit (F). Differentiation between six (morpholine) and seven (oxazepine)
membered ring adducts was possible by the use of enone 5 derivative, which contains an extra methyl group attached to the enone beta carbon. The super-
position of morpholine (green) with oxazepine (light gray) modeled adducts is shown in (G) and a detailed view of 5 binding the ChTL subunit is shown in (H). The
Fo-Fc difference map calculated from experimental data after modeling the oxazepine ring is contoured at 3s (G). Positive and negative peaks are presented in
green and red nets, respectively. Extra electron density near the wrong N-Cb bond (red net) and missing density at the extra methyl position for morpholine ring
possibility (green net) were found, indicating the correctness of the 6-membered morpholine ring as the final product. Sequence numbering is based on the
primary sequence alignment of the respective yeast subunit with that of Thermoplasma (Lo¨we et al., 1995). Figures were generated with the Pymol software
(Schroedinger). Oxygen, nitrogen, and sulfur atoms are shown in red, blue, and yellow, respectively.
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tion of the proteasome.
Enone 4 also exhibited this inhibition profile in the ChTL
subunit, thus suggesting a similar stepwise reaction with the
proteasome (Figures S1G–S1I). Compound 4 had a prolonged
reversible phase, with reversible profiles at 2 and 6 hr of inhibitor
incubation with the enzyme, indicating a less favored irreversible
reaction step when compared to epoxyketones. We further
measured the proteasome TL activity, showing that epoxyke-
tones 1 and 3 are irreversible, whereas enone 4 is a reversible in-
hibitor of this proteasome catalytic unit (Figures S1J–S1L).
Taken together, these results suggest a different mode of pro-
teasome binding for the a,b-unsaturated carbonyl system in
compound 4. Although one might anticipate the enone moiety
of 4 to function as a one-step covalent irreversible inhibitor
undergoing a 1,4-Michael reaction such as compound 2 (Groll
et al., 2008), the reversible nature of the first step of inhibition
observed for compound 4 precludes the possibility of a 1,4-addi-
tion, which would lead to an irreversible adduct. Furthermore,784 Chemistry & Biology 21, 782–791, June 19, 2014 ª2014 Elsevierthe binding data of enone 4 is similar to that observed for
epoxyketone inhibitors 1 and 3, showing a first reversible and a
second irreversible reaction stepwith the proteasomeChTL sub-
unit, thereby suggesting the likelihood of a 1,2-addition on the
ketone of compound 4 as the first reversible step.
Crystal Structures
To characterize the binding modes of the carmaphycin deriva-
tives, compounds 1, 3, and 4 were crystallized with the yeast
20S proteasome and diffraction data collected to 2.8 A˚ resolu-
tion (Figures 2 and S3). All three structures were refined to final
Rfree values below 24.3% and root-mean-square deviation
bond and angle values less than 0.006 A˚ and 1.0, respectively
(Table S1).
Using inhibitor concentrations in the millimolar range for crys-
tal soaking, compounds 1, 3, and 4 targeted all three active sites
of the proteasome through covalent linkages, establishing that
they are catalytically active in the crystalline state (Figure S3A).
The backbones of bound inhibitors were well defined asLtd All rights reserved
Figure 3. Detail of the Reactive Center of the Proteasome Catalytic
Subunits as Found in the Crystallographic Structures of 2 and 4 in
Complex with the 20S Proteasome
The Thr1Og is the general nucleophile, but the electrophile can vary depending
upon warhead accommodation at the reactive center. The a,b-unsaturated
amide and carbonyl systems of proteasome inhibitors 2 (pale yellow; Protein
Data Bank ID 2ZCY) and 4 (green) are superposed at the TL (b2) catalytic unit.
The Cb of 2 is in prone position for an irreversible 1,4 addition type nucleophilic
attack by Thr1Og. On the other hand, the carbonyl of 4 and the carbonyl of the
natural peptide substrate (not shown) are positioned to undergo reversible 1,2
addition. Figures were generated with the Pymol software (Schroedinger).
Oxygen, nitrogen, and sulfur atoms are shown in red, blue, and yellow,
respectively.
Table 2. Interaction of the Proteasome Catalytic Center with the
Natural Substrate and Inhibitors
Substrate/Inhibitor Electrophile Reaction Nucleophile
Natural substrate Carbonyl (C) 1,2-addition Og from Thr1
Compound 1 Carbonyl (C) 1,2-addition Og from Thr1
Compound 2 b carbon (Cb) 1,4-addition Og from Thr1
Compound 4 Carbonyl (C) 1,2-addition Og from Thr1
Reaction types, nucleophiles, and electrophiles involved are described.
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atoms of residues Gly47N, Gly47O, Thr21N, Thr21O, and
Ala49N as well as the side chain of Asp126 (Figure 2). The P1
leucine side chain was in proximity to the structurally rearranged
Met45, as well as Ala20, Val31, and Ala49 in the S1 pocket. The
methionine sulfoxide (via 1) and N,N-dimethylglutamine (via 3
and 4) P2 side chains were equally aligned and did not form
any direct interactionwith protein residues. The P3 valine residue
was effectively stabilized in the S3 pocket by three alanine resi-
dues (Ala20, Ala22, and Ala27), whereas a hydrophobic cluster
comprised of Pro104, Tyr106, Pro127, and Val128 accommo-
dated the hexanoate tail in the ChTL (b5) and TL (b2) sites. This
aliphatic group was exposed to solvent in the b1 subunit
(caspase-like activity), where it adopts a random arrangement
(Figure S3A).
Structural refinement and electron-density map calculations
revealed that the epoxyketone inhibitors 1 and 3 bind to the
Thr1 residue in a manner highly similar to that previously
observed for epoxomicin (Groll et al., 2000; Huber et al., 2012)
and its derivatives (Figure S3B). Unambiguously, a morpholine
ring was formed between the catalytic Thr1 residue and the
epoxyketone warheads (Figures 2A–2C), as a result of a two-
step reaction between the protein and the inhibitors. As previ-
ously reported (Huber et al., 2012), the 1,2-addition of Thr1Og
to the carbonyl carbon of the a0,b0-epoxyketone first occurs to
form a hydrolysable hemiketal adduct. Subsequently, the
epoxide group is prearranged for a nucleophilic attack by the
Thr1 free N-terminal amine nitrogen. This reaction occurs at
the C2 position of the epoxide and results in the final morpholine
ring product (Figures 2A–2C), which is stabilized by interactions
with Lys33Nε and Ser129Og.Chemistry & Biology 21,In contrast, enone 4 adopts two different ligand states in the
crystal structure that give insight into the observed partial revers-
ibility of 4 (Figures 2D–2F). The electron densities calculated for
the TL subunit in the 2FO-FC omit as well as in the FO-FC differ-
ence maps clearly displayed the attachment of 4 to Thr1Og via
a hemiketal linkage involving the carbonyl group of the ligand
(Figure 2E). The resulting alkoxide is stabilized in the oxyanion
hole, interacting with the main chain of Gly47NH, similar to that
observed in an epoxyketone-derived intermediate recently re-
ported (Huber et al., 2012). The preference for a 1,2-addition
over a 1,4-addition to the a,b-unsaturated system of 4 (Figure 2E)
might be a consequence of warhead accommodation at the
proteasome reactive center (Figure 3 and Table 2). Compound
4 positions the carbonyl of the enone in a position for nucleo-
philic attack by the Thr1Og nucleophile, thus enabling the
1,2-addition reaction. This scenario is different with 2, which
positions the b carbon of its a,b-unsaturated system at this reac-
tive site, thus facilitating a 1,4-addition (Groll et al., 2008).
Structural inspection of the ChTL and caspase-like sites, on
the other hand, revealed that enone 4 binds in an alternative
mode at these catalytic centers (Figure 2F). Notably, 4 forms a
cyclic adduct with the Thr1 residue involving both the ketone
and alkene functional groups. Inspection of the diffraction data
at 2.8 A˚ resolution and molecular fitting, however, did not un-
equivocally differentiate whether the cyclic product involved a
6-membered morpholine ring or a 7-membered oxazepine ring.
Both adducts are structurally distinct and would involve different
mechanistic paths. In a first hypothesis, the hemiketal intermedi-
ate of 4, as observed in the TL subunit (Figure 2E), would
undergo an unprecedented hydroamination reaction at the
alkene residue with Thr1N. Depending on the regiochemistry of
the reaction, two outcomes are plausible and would generate
either morpholine or oxazepine adducts.
Formation of the oxazepine, however, could alternatively be
achieved by a different reaction mechanism first involving a
1,4-addition of Thr1N to the enone followed by addition of the
Thr1Og to the ketone (Figure S10). In this scenario the first cova-
lent adduct would represent the irreversible product derived
from 1,4-addition and the proteasome nucleophile would
change from Thr1Og to Thr1N. Considering that Thr1Og is the
general nucleophile reported in all proteasome covalent interac-
tions to date, including the innate proteolytic mechanism (re-
viewed in Kisselev et al., 2012), and that Thr1N is protonated
under physiological conditions, it is unlikely that Thr1N should
act as the initial nucleophile. Furthermore, our reversibility exper-
iments clearly show that 4 undergoes a stepwise reaction with
the proteasome, in which the first step is reversible (Figures
S1G–S1I). While this orthogonal mechanism is not consistent782–791, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 785
Figure 4. Quantum Chemical Calculations of the Regiochemistry of
the ChTL Site Alkene Hydroamination of Inhibitors 4 and 5
(A and B) Computed structures (distances are approximate) of models for (A)
the morpholine product and (B) a possible alternative oxazepine product and
their computed relative free energies (kcal/mol).
(C) Model system used to examine proton transfer to carbon a versus
carbon b. The transition state structure for proton transfer to Cb is favored by
5 kcal/mol over that for transfer to Ca.
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proteasome biochemistry, our structural data did not unequivo-
cally rule it out.
To address this issue, we designed compound 5 as a struc-
tural probe to help discern between the six- and seven-
membered ring formation scenarios. Compound 5 contains an
additional carbon atom at the g position of the enone. If the
cyclized product was morpholine-based, then an ethyl side
chain would be expected. On the other hand, an oxazepine-
based adduct would be reflected by two adjacent methyl
groups. The crystal structure of the proteasome bound to 5,
obtained at 2.5 A˚ resolution (Table S1), revealed a cyclized
adduct occupying proteasome binding pockets similar to those
observed with analogs 1, 3, and 4 (Figure 2H). Importantly, we
clearly saw the telltale ethyl side chain in the 2FO-FC omit map
of 5 binding the proteasome (Figure 2H) and, further inspection
of the FO-FC differencemapswas consistent only with amorpho-
line cyclic product (Figure 2G). These data definitely exclude a
1,4-addition mechanism and reveal that the regiochemistry of
the hydroamination reaction proceeds in a Markovnikov sense
in generating the morpholine ring as final product.
Quantum Chemical Calculations
To further evaluate the reactivity of enone 4with the proteasome,
we modeled transition state structures for 1,2- and 1,4-addition
as the first reaction step (Figures S4–S6), in the absence of the
surrounding active site, using density functional theory calcula-
tions (M06-2X/6-31+G(d,p); see Experimental Procedures and
Supplemental Experimental Procedures for details). The data
indicate that the 1,2-addition (Figure S5) is favored over the
1,4-addition (Figure S6) by approximately 1 kcal/mol. We further786 Chemistry & Biology 21, 782–791, June 19, 2014 ª2014 Elsevierinvestigated the regiochemistry of the ChTL site alkene hydroa-
mination of 4 and 5, by calculating the relative energies of both
reaction products and transition state structures for formation
of their carbocation precursors. These calculations indicate
that 4 has an inherent thermodynamic and kinetic preference
formorpholine over oxazepine ring formation (Figure 4). Themor-
pholine product is predicted to be approximately 8 kcal/mol
lower in free energy than the oxazepine product (Figures 4A
and 4B). In addition, proton transfer (the first step in the hydroa-
mination reaction) to the alkene CH2 group is predicted to be
favored over proton transfer to the more substituted carbon by
5 kcal/mol (Figure S9), as expected.
These theoretical calculations are in agreement with the
experimental results, leading to a consistent mechanistic model
in which the enone warhead in 4 undergoes an initial 1,2-addi-
tion, followed by hydroamination of the alkene, which occurs in
a Markovnikov sense, leading to a morpholine ring as the final
product.
DISCUSSION
As with the well-studied epoxyketone pharmacophore first
described with the proteasome inhibitor epoxomicin (Groll
et al., 2000), we show here that the enone functional group
supports a two-step reaction leading to a cyclic adduct
formation. The ketone groups of both electrophilic inhibitors
are first attacked by the proteasome Thr1Og, followed by a sec-
ond attack of the Thr1N on either the epoxy or alkene groups
(Figure 5).
Based on the complementary results from our quantum chem-
ical calculations and the crystallographic data obtained with
compound 5, we demonstrated that a morpholine ring, as
observed in epoxyketone proteasome inhibitors, is also gener-
ated in the case of the enone pharmacophore. The general ligand
binding in the proteasome-inhibitor complexes of epoxyketones
1 and 3 and enones 4 and 5 is identical (Figure S3), andmarkedly
different to that observed in the 2-derived proteasome complex
(Groll et al., 2008; Figure 3). Consequently, the proteasome inhi-
bition mechanism suggested for enones 4 and 5 is more similar
to that verified for its parent scaffold-containing compounds 1
and 3 than to that for its parent warhead-containing compounds
as in 2 and vinylsulfones (Kisselev et al., 2012; Figures 3 and 5).
Contemplating the reaction mechanism of the proteasome
with inhibitor 4, we considered several scenarios to dissect the
mechanism of enzyme inhibition by this enone compound. First,
the hemiketal intermediate is formed following the classical pro-
teasome 1,2-addition mechanism involving the Thr1Og nucleo-
phile and the inhibitor carbonyl, which is ideally positioned at
the proteasome reactive center (Figure 3). After the formation
of the hemiketal intermediate, the alkene residue is no longer
activated. Thus, attack by the Thr1 amino group may proceed
either directly with the isolated olefin (Figure 5C) or indirectly
(Figure 5D).
While the aminolysis of epoxides is known to occur in water
under mild conditions, the direct hydroamination of an inacti-
vated alkene (Figure 5C), although thermodynamically feasible,
generally requires a catalyst (Hultzsch, 2005). The geometric re-
strictions conferred by the hemiketal intermediate, however,
should favor hydroamination, which is otherwise prohibited inLtd All rights reserved
Figure 5. Proposed Reaction Mechanisms
Involving the Proteasome Active Site Resi-
due Thr1 and Inhibitors Containing Different
Reactive Functional Groups
(A–D) Inhibitory reaction mechanisms are shown
for (A) the epoxyketone warhead in epoxomicin
(Huber et al., 2012, Wei et al., 2012) and 1, (B) the
natural a,b-unsaturated-amide system present in
2 (Groll et al., 2008), and (C and D) the enone
warhead in the synthetic derivatives 4 and 5.
Chemistry & Biology
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facilitated by proton transfer from the free Thr1 amine to the C-C
double bound, because the free amine is predicted to be proton-
ated. The geometric restrictions conferred by the hemiketal bond
and the overall ligand and warhead positioning in the enzyme
binding pocket further reduce the entropic penalty for amine
approach to the alkene p-bond. In addition, the Ser129Og side
chain is approximately 3 A˚ from the Thr1 amine nitrogen atom
in both cyclized and hemiketal adducts. Consequently, the
placement of this residue at this proximate positionmay increase
the nucleophilicity of the amine, thereby facilitating amine addi-
tion to the alkene (Schlummer and Hartwig, 2002).
An alternative mechanism involving an indirect hydroamina-
tion reaction is also plausible (Figure 5D). Here the hemiketal in-
termediate may first undergo an intramolecular rearrangement in
which the generated alkoxide reacts with the adjacent olefin, the
latter requiring activation by an acidic proton. This newly formedChemistry & Biology 21, 782–791, June 19, 2014epoxide intermediate would then react
with the free amine from Thr1 to complete
the reaction and form the morpholine
adduct. Thismechanistic pathway is sup-
ported by quantum chemical calculations
that predict barrierless formation of the
epoxide intermediate (in the gas phase),
and consequently, align the inhibitory
mechanisms of the epoxyketone and
enone functional groups.
Irrespective of the mechanistic route,
the energetic barrier for the final step in
the morpholine ring formation from the
enone is expected to be greater than
that of the epoxyketone, which may
explain the decreased potency (Table 1)
and partial reversibility of derivative 4
(Figure S1). Interestingly, when the func-
tional group adjacent to the ketone is
removed as in acylketone 6, proteasome
inhibition potency and cell activity are
both abolished. This observation further
suggests that the reactive epoxide and
alkene functional groups are key to avoid-
ing rapid hydrolysis of the initially formed
hemiketal adduct. The nature of the
warhead functional group and viability of
the second reaction step to form an irre-
versible final product strongly contributes
to the potency of these agents (Table 1).Although derivatives of 4 have not yet been observed in nature,
recent biosynthetic studies of the epoxyketone proteasome in-
hibitors epoxomicin and eponemycin suggest the biosynthetic
intermediacy of enone intermediates in those natural products
that may foretell their future discovery (Schorn et al., 2014).
The modulated reactivity observed with compound 4 is some-
what reminiscent of the potent proteasome inhibitor fluoro-
salinosporamide, which also reacts with the proteasome in a
two-step reaction mechanism involving a fast and reversible
attachment to Thr1 followed by a slow and irreversible fluoride
displacement reaction (Eusta´quio and Moore, 2008; Groll et al.,
2009). A major difference between these two inhibitors involves
the nature of the reversibility of the initial proteasome adducts.
In the case of fluorosalinosporamide, the b-lactone warhead is
destroyed upon hydrolysis, whereas in compound 4, the reverse
reaction of the hemiketal intermediate would restore the reactive
enone warhead.ª2014 Elsevier Ltd All rights reserved 787
Figure 6. Synthetic Scheme Leading to Carmaphycin Analogs 3–6
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myeloma in 2012 sparks hope for a broader application of pro-
teasome inhibitors as pharmaceutical agents, especially with re-
gard to their unexploited potency for treatment of other cancer
subtypes and immunological diseases. Although carfilzomib
shows decreased side effects compared to bortezomib, it still
suffers from its highly reactive warhead and toxic effects with
prolonged use (Arastu-Kapur et al., 2011). Increasing the revers-
ibility window with the newly established enone mechanism of
action may be a promising approach to further improvements
in this inhibitor class.
In summary, our data reveal that the a,b-unsaturated
carbonyl systems in compounds 4 and 5 bind in an inverted
orientation with respect to warhead positioning reported for 2,
thereby allowing for the initial attack on the carbonyl versus
the conjugated alkene (Figures 3 and 5). This inversion of the
innate chemical properties of the Michael-system can be
ascribed to reactive group positioning for nucleophilic attack
by Thr1Og (Figure 3). We demonstrated that the remaining
alkene derived from the enone warhead of compounds 4 or 5
can undergo a second nucleophilic attack by proteasome
Thr1N, leading to a cyclic morpholine adduct. Although this
second reaction is slower, it is ultimately essential for inhibitor
potency. We anticipate that alkene hydroamination could be
exploited for enzyme inhibitor design in situations where a
nucleophile and an acid are in proximity and under ideal geo-
metric constrains to the target alkene, allowing for an otherwise
entropically unfavorable reaction to yield a stable enzyme
adduct.788 Chemistry & Biology 21, 782–791, June 19, 2014 ª2014 ElsevierSIGNIFICANCE
The proteasome is a validated biochemical target for cancer
chemotherapy and is inhibited by natural products and
synthetic molecules, following reversible or irreversible
reaction mechanisms. The proteasome Thr1 catalytic resi-
due actively participates in the inhibitory mechanisms
through its side chain oxygen (Thr1Og) and its terminal
amine (Thr1N) nucleophiles that attack the inhibitor’s
warhead electrophiles. We here report the crystal structures
of the yeast 20S proteasome bound to carmaphycin and its
derivatives containing epoxyketone and enone warheads,
together with cell-based and mechanism-based assays.
These data, along with quantum chemistry calculations,
reveal previously unknown proteasome inhibitory biochem-
istry showing that the enone compounds are partially
reversible and display promising biological properties. The
proposed mechanism for the newly established enone pro-
teasome inhibitor electrophile involves a two-step reaction,
involving a 1,2-addition of Thr1Og to the ketone, followed by
a hydroamination reaction of the inhibitor’s inactivated
alkene by Thr1N. This is an example of enzyme inhibition
by hydroamination, and the suggested mechanism is well
supported by the data presented. We were able to trap the
reaction intermediate for the enone inhibitor in crystal struc-
tures, showing that warhead positioning in the enzyme
active center is essential for defining the nature of chemical
interactions with the Thr1Og nucleophile. In the carmaphy-
cin derivatives series, the carbonyl moiety of epoxyketoneLtd All rights reserved
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Thr1Og, resulting in a reversible hemiketal adduct as the
first reaction product. The second reaction step involves
the covalent attachment of Thr1N to the epoxide or to the
alkene, following intramolecular aminolysis or hydroamina-
tion, respectively. Hydroamination is slower than aminolysis
and represents a new chemical reaction for enzyme inhibi-
tion that allows for controlling the irreversibility of protea-
some inhibitor binding.
EXPERIMENTAL PROCEDURES
Chemicals
All chemicals used in the present work were of reagent grade quality.
Crystal Structures
The 20S proteasome was purified from Saccharomyces cerevisiae as
described previously (Gallastegui and Groll, 2012; Groll et al., 1997; Groll
and Huber, 2005). Crystals were grown in hanging drops at 24C, using a pro-
tein solution at 40 mg/ml in 10 mM morpholino-ethane-sulphonic acid (MES)
pH 7.5 and EDTA (1 mM). Drops contained 1 ml of protein and 1 ml of the reser-
voir (30 mM of magnesium acetate, 100mM of MES [pH 7.2] and 12% ofMPD)
solutions (Groll et al., 1997; Groll and Huber, 2005). Crystals were soaked with
compounds 1, 3, 4, 5, or 6 at final concentrations ranging from 2 to 10 mM for
24 hr. Crystals were then transferred to a cryoprotecting buffer (30% 2-methyl-
2,4-pentanediol, 20 mM magnesium acetate, 100 mM Tris [pH 6.9]) before
cooling in liquid nitrogen.
Data collections were carried out at 100 K in a stream of liquid nitrogen gas
(Oxford Cryo Systems). Crystals formed in the P21 space group with cell
dimensions of about a = 135 A˚, b = 301 A˚, c = 144 A˚ and b = 113 (Table
S1). Data to 2.5 A˚ were collected using synchrotron radiation with l = 1.0 A˚
at the X06SA-beamline in SLS/Villingen/Switzerland. X-ray intensities and
data reduction were evaluated using the XDS program package (Kabsch,
2010). Conventional crystallographic rigid body, positional, and temperature
factor refinements were carried out with PHENIX (Adams et al., 2010) using
the yeast 20S proteasome structure as starting model (Protein Date Bank
accession code 3UN8; Huber et al., 2012). Cycles of maximum likelihoodmini-
mization, solvent modeling, and anisotropic correction were conducted in
PHENIX (Adams et al., 2010), using grouped B-factor and noncrystallographic
symmetry refinement. Real space refinement and inhibitor modeling were con-
ducted using Coot (Emsley and Cowtan, 2004). Ligand construction, geometry
file elaboration, and covalent ligand-protein linkage were carried out using
JLigand (CCP4, 1994) and Avogadro software. The last step of refinement
was performed in Refmac5 (Murshudov et al., 1997), using noncrystallo-
graphic symmetry and TLS refinement.
Omit maps were calculated using the program Omit (Bhat, 1988).
Inhibition Measurements
Inhibition assays of the purified 20S proteasome core particle from
S. cerevisiae was conducted as previously reported (Pereira et al., 2012),
with minor modifications. One nanomolar of proteasome was incubated with
different inhibitor concentrations in Tris 25 mM pH 7.5; SDS 0.03%; EDTA
0.5 mM for 15 min at 37C in 96-well plates, in a final reaction volume of
40 mL. Ten microliters of specific fluorogenic proteasome substrate Suc-
LLVY-Amc (CTL substrate) or Ac-LRR-Amc (TL substrate) at 200 mM were
added, resulting in a final substrate concentration of 40 mM. Samples were
incubated for 15 min at 37C and then the fluorescence in each well was
measured. Fluorescence was normalized to the control conducted in the
same conditions, however without inhibitor (related to 100% of enzyme activ-
ity), and plotted on a graph of inhibitor concentration versus remaining enzyme
activity. The experimental data were fitted using the logistic four parameters
equation in GraphPad software version 5 (GraphPad Prism).
Cell Assays
Cytotoxicity to H-460 human lung cancer and HCT-116 human colon cancer
cell lines was determined as previously reported (Mevers et al., 2011; GrossChemistry & Biology 21,et al., 2010; Tidgewell et al., 2010) with cell viability being determined by
MTT reduction.
Reversibility Experiments
Yeast or human 20S proteasomes (10 nM) were incubated with 1 mM of inhib-
itor 4 or 0.01 mMof 1 or 3 for 2, 6, or 24 hr (yeast) or 1 hr (human) in Tris 100 mM
pH 7.0. The proteolytic activity was measured with fluorescence, using ChTL
(Suc-LLVY) or TL (Ac-LRR) 7-amino-4-methylcoumarin chromophoric sub-
strates after 10-fold dilution of the protein and inhibitor. A control group main-
tained at the same experimental conditions but with constant initial inhibitor
concentration ([4] = 1 mMor [1] or [3] = 0.01 mM)was performed for comparison.
Protein activity in groups maintained at the same experimental condition,
however in the absence of the inhibitor (DMSO control) was monitored to
guarantee protein integrity during the different time points (Figures S1G–S1I
in black). ChTL activity was stable up to 24 hr. However, TL catalytic activity
was unstable in the incubation buffer after the first 4 hr; therefore, only data
derived within the first 2 hr of incubation are reported for this latter enzyme
activity.
Computational Details
All calculations were carried out using the M06-2X/6-31+G(d,p) method
(Hohenstein et al., 2008; Zhao and Truhlar, 2008) with a continuum treatment
for solvation (the SMD approach [Marenich et al., 2009], using chloroform, i.e.,
a solvent with a dielectric constant in the range of estimates for enzyme active
sites), as implemented in Gaussian 09 (Gaussian). Explicit active site residues
were not included in the calculations, so the preferences described here reflect
inherent reactivity. Conformations of computed structures represent produc-
tive conformations for formation of the morpholine and oxazepine products.
Structural drawings were produced using Ball & Stick (Mu¨ller et al., 2004).
Computations on proton transfer did not include solvent and were carried
out using the model system shown in Figure 4C in the main text. N–H and
Ca/b–H distanceswere frozen to 1.30 A˚ for the two systems shown in Figure S9
and the remainder of each system was allowed to fully relax. The 5 kcal/mol
energy difference discussed in the main text corresponds to the difference
in electronic energies between these two optimized structures.
Synthesis
Compounds 7, 9, 12, and 15 were synthesized as previously described (Per-
eira et al., 2012) and compounds 3–6 were synthesized according to Figure 6.
Detailed synthetic procedures are reported in the Supplemental Experimental
Procedures.
Optical rotations were measured on a JASCO P-2000 polarimeter. UV and
infrared spectra were recorded on a Beckman DU800 spectrophotometer
and on a Nicolet 100 FT-IR spectrometer, respectively. 1H, 13C, and two-
dimensional nuclear magnetic resonance spectra were collected at a 1H reso-
nance frequency of either 400 MHz (Varian Mercury), 500 MHz (Varian VX500),
or 600 MHz (Bruker Avance III equipped with 1.7 mm and 5 mm TCI cryo-
probes). Chemical shifts were calibrated internally to the residual signal of
the solvent in which the sample was dissolved (CDCl3, dH 7.26, dC 77.0).
High-resolution mass spectra were obtained on a ThermoFinnigan MAT900XL
mass spectrometer or an Agilent Technologies 6530 Accurate-Mass Q-time-
of-flight liquid chromatography/mass spectrometer. High-performance liquid
chromatography was carried out using a dual Waters 515 pump system equip-
ped with a Waters 996 photodiode array detector. Vacuum and flash chro-
matographic separations were performed using type H (10–40 mm, Aldrich)
silica and silica gel 60 (40–63 mm, EMD), respectively. Merck thin-layer chro-
matography (TLC) sheets (silica gel 60 F254) were used for analytical TLC
(aluminum-supported, layer thickness 200 mm) and preparative TLC (glass-
supported, layer thickness 250 mm). All chemical reagents were obtained
from Aldrich in an analytical or higher grade and were used as received unless
stated otherwise. Solvents were acquired as high-performance liquid chroma-
tography grade. All reactions were performed under dry nitrogen using glass-
ware previously oven dried (150C), unless otherwise specified. Glassware
was allowed to reach room temperature under a flow of inert gas. Likewise,
glass syringes and stainless steel needles, used to handle anhydrous reagents
and solvents, were oven dried, cooled in a desiccator, and flushed with inert
gas prior to use. Anhydrous THF was purchased from Aldrich or distilled
from sodium/benzophenone; CH2Cl2 was distilled from CaH2.782–791, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 789
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The Protein Data Bank accession numbers for the proteasome binding com-
pounds 1, 3, 4, and 5 reported in this paper are 4HRD, 4HRC, 4HNP, and 4TLC.
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